New Delhi: Amid concerns over Omicron variants rising, India’s COVID-19 task force chief VK Paul on Tuesday said there is a possible scenario that “our vaccines may be ineffective in emerging circumstances” and that the vaccines may need to be modified. The vaccine that produces a vaccine may need to be modified. Need to be in ready condition.
Speaking at an event organized by industry body CII, Paul also stressed on the need for a vaccine platform that adapts quickly with the changing nature of variants.
“We have experienced delta shock and now Omicron shock… A possible scenario is that our vaccines may be ineffective in emerging situations in view of the last three weeks of living with Omicron, we have seen how such doubts surfaced. Some of them may be real, we still don’t have the final picture,” he said.
Read more | Omicron spreading so fast not seen with any other covid variant: WHO
According to Paul, drug development will not be out of fashion for the next viral pandemic/pandemic that the world may face, and that the anti-microbial resistance challenge is also a cry for drug solutions.
“How quickly can we make a vaccine that’s using the same platform, but now targeted for the type of day… we may have to think about how we do it.
“… Moving on from the rapid development of a generic vaccine, we have to be prepared for a situation where we are able to modify vaccines as needed. It may not happen every three months but it may be every three months Maybe. Years maybe. So, that needs to be taken into account,” Paul said.
The new COVID variant called B.1.1.529 or Omicron was first reported from South Africa to the World Health Organization (WHO) on 24 November.
According to Paul, drug development will not be out of fashion for the next viral pandemic/pandemic that the world may face, and that the anti-microbial resistance challenge is also a cry for drug solutions. Noting how the roadmap and risk-taking attitude of India’s classical pharmaceutical industry needs to be examined, he said, “We are still crying out for an effective drug to fight viral diseases including COVID. Huh”.
“While the pandemic is not over, we will continue to deal with uncertainty, even as we continue to move towards endemicity in hopes of a mild disease that we can deal with,” Paul said. taken for granted.
Noting that the industry’s contribution to science in the country is low, Paul said, “our national investment in science is all public money … even during the development of vaccines, a lot of testing was done in the national laboratory”.
Furthermore, he said that 97 percent of the vaccines given to the Indian people were from public money and very little from private money.
Paul said that the most important priority right now is to ensure that there is universal coverage of the vaccine and no one is left behind, Paul said that globally there are 3.6 billion people who are not vaccinated.
“We need 7.2 billion doses together, and with the current rate of production, it is within our understanding … it is possible for us to deliver the vaccine,” Paul said.
(with PTI inputs)
See below health equipment-
Calculate your body mass index (BMI)
,